Second-trimester maternal serum screening (MSS) for Down syndrome has been widely used in routine prenatal care in developed countries. The screening combines maternal age-specific risk of Down syndrome with risk estimation obtained by measuring maternal serum markers to assign women an expected risk of having a term Down syndrome pregnancy. Diagnostic tests were offered to women whose risk exceeded the risk cutoff determined by the screening program. The commonly used triple test, which involves the use of maternal age, serum ␣-fetoprotein, unconjugated estriol, and human chorionic gonadotropin, was expected to have a Down syndrome detection rate of 60 -65% and false-positive rate of 5% (1 ) . Although the expected screening performance has been achieved in many screening programs, the accuracy of individual risk calculated by a relatively complex computation based on a statistical model was not immediately obvious. Good agreement between the expected risk of Down syndrome and observed prevalence has been reported previously in several screening programs (2) (3) (4) (5) . We evaluated the accuracy of expected risk of Down syndrome in a large provincial, multiple test center, MSS program in Ontario, Canada.
MSS has been coordinated at the provincial level in Ontario since 1993. Triple maker screening (␣-fetoprotein, unconjugated estriol, and ␤-human chorionic gonadotropin) was carried out in seven regional laboratory centers. Information including screen utilization, results, follow-up data, and the pregnancy outcomes of all women screened in the seven centers was collected in the Ontario MSS database. Data on outcomes for all pregnancies screened were obtained through the Canadian Institute of Health Information, which records every hospital admission in Canada. Where necessary, information was verified through provincial genetic-counseling centers and cytogenetic laboratories. Using this protocol, we obtained 94.4% of outcomes.
The study was based on 311 256 women screened in the Ontario MSS program between October 1993 and September 1998. Of the 311 256 women screened, a Down syndrome risk level was recorded for 301 700, and 284 804 (94.4%) of them had outcome data from Canadian Institute of Health Information, including 506 pregnancies associated with Down syndrome. The expected risks of a term Down syndrome pregnancy were calculated with AFP Expert (Benetech). The risk cutoff used in the Ontario MSS program was 1 in 385.
Using a technique described by Wald et al. (2 ), we ranked the women screened according to their individual expected risk of Down syndrome. They were divided into 10 groups, each group containing 44 -59 cases of Down syndrome pregnancies. Two factors were considered when grouping the cases: (a) that each risk group covered an appropriate risk range; and (b) that there was a similar number of cases in each group. The mean expected term risks of an affected pregnancy were calculated for each Clinical Chemistry 48, No. 4, 2002 group. The risks were then compared with the observed risks (prevalence) of that particular group (2 ). Because it was estimated that 23% of Down syndrome pregnancies will abort spontaneously after 16 weeks of gestation, cases with positive screening results (risk, Ն1 in 385 in our program) and diagnosed prenatally were multiplied by 77% to allow for the spontaneous fetal losses (6 ). Table 1 compares the expected risk of Down syndrome with its observed prevalence; it gives the risk category, the mean expected risk, number of Down syndrome cases, adjusted number of Down syndrome cases, and observed birth prevalence of Down syndrome for each group of women. The mean expected risks were close to the observed prevalence across all the risk groups, particularly for women with very high expected risks (women in risk groups 1 in 8 or greater, 1 in 9 to 1 in 25, and 1 in 26 to 1 in 45).
The logarithmic transformed mean expected risks of Down syndrome are plotted against the logarithmic transformed observed prevalence in Fig. 1 . The plot shows that the mean expected risk of Down syndrome was close to the observed prevalence (R 2 ϭ 0.9901). Good agreement between the expected and observed risks of Down syndrome has been reported in several studies. Wald and colleagues (2, 4 ) described a technique that can be used to validate the expected risk of Down syndrome. Using this method, they compared expected risk of Down syndrome with the prevalence observed in their screening program. The studies consisted of approximately 120 000 women screened, including 153 cases of Down syndrome screened with the triple test and 86 cases of Down syndrome screened with the quadruple test. The results showed that the estimated risks were accurate across the entire range of risks (2, 4 To our knowledge, our data set is the largest for assessing agreement between expected and observed risks of Down syndrome. Our results showed that the expected risks of Down syndrome assigned to individual women were close to the observed risks across all the risk ranges. The expected risks and observed risks for women in high risk groups (risk Ն1 in 45) were almost identical.
We examined the completeness of the ascertainment of Down syndrome in our study population by comparing the expected number of Down syndrome cases with the number identified through the screening program. The expected number of Down syndrome births was estimated by applying the age-specific Down syndrome risk to the age distribution of women screened with an available outcome. In our study population, we would have expected 444 Down syndrome births in the absence of prenatal diagnosis and selective termination. After adjusting for spontaneous fetal losses, we would have expected 424 term Down syndrome pregnancies. The rate of ascertainment was consistent with that reported by Canick and Rish (3 ) in a similar, but small-scale, study. We have also estimated the completeness of this ascertainment by adding the actual observed number of Down syndrome births to the number terminated or lost spontaneously, multiplying by 0.77 to adjust for the spontaneous fetal losses. Using this adjustment, we identified 439 cases of term Down syndrome, a number very close to the expected 444 cases.
In conclusion, the expected risk assigned to the individual woman in the Down syndrome serum screening program is accurate, reflecting the term risk of having a fetus with Down syndrome.
We thank all members of the Ontario MSS consultative committee and participating MSS centers for their contributions to the Ontario MSS program. We also thank the women of Ontario for supporting the MSS program. Multiple myeloma is a malignant plasma cell dyscrasia characterized by bone marrow plasmacytosis (1 ). Malignant plasma cells produce an abnormal monoclonal immunoglobulin, the laboratory hallmark of the disease process, as well as cytokines, which stimulate cells of the bone marrow microenvironment (2, 3 ) . The neoplastic clone and its products cause the dysfunction of several organs, including bone pain or fractures, renal failure, anemia, susceptibility to infection, hyperviscosity, and hypercalcemia (1 ) . However, the most characteristic feature of multiple myeloma and other monoclonal gammopathies is the presence of a serum and/or urinary monoclonal (M) component on immunofixation (4 ). Approximately two-thirds of patients with a serum M component also have Bence Jones proteins (BJPs) in the urine. In almost 20% of myelomas, only immunoglobulin light chains are present in the serum and/or urine and are often designated as light chain multiple myeloma (LCMM).
Renal failure occurs in ϳ25% of myeloma patients, and there is some renal pathology in more than one-half (1, 5, 6 ) . The number of patients with renal disease varies considerably depending on the criteria used to define renal impairment. Serum creatinine concentrations remain in the reference interval until the glomerular filtration rate is reduced by almost 50%; therefore, the data obtained with blood creatinine concentrations most likely underestimate the incidence of renal involvement in myeloma. Data using the estimated creatinine clearance rate (7 ), which takes into account various variables, including patient age, weight, and gender, indicate that approximately one-half of patients have renal insufficiency at the time of diagnosis (5 ). The nature of the M component is also associated with the prevalence of renal disease (5, 8, 9 ) . In light chain myeloma, 65% of patients have impaired renal function at the time of diagnosis when estimated creatinine clearance is used as the variable (5 ). The incidence of renal dysfunction is greater in patients with compounding factors, such as hypercalcemia and advanced disease (5, 8, 9 ) . Although there are numerous contributing factors for renal dysfunction in myeloma, the primary among them is the filtration of large quantities of light chains by the glomeruli (10, 11 ), which produces a huge reabsorptive load on the proximal tubules.
Tubular dysfunction is seen in Ͼ98% of patients with Bence Jones proteinuria Ͼ1 g/24 h (9 ). However, tubular damage associated with the excretion of light chains is almost always present (10 ). Usually, because light chains are of low molecular weight (ϳ25 000), they are readily filtered by the glomeruli, reabsorbed in the renal tubules, and catabolized. If the filtered load is excessive, as occurs in LCMM, this reabsorptive capacity is exceeded and free light chains appear in the urine, where they have also been concentrated by physiologic renal tubular water reabsorption. Tubular damage results either directly from light chain toxic effects or indirectly from the release of intracellular lysosomal enzymes (10 ). The proteinuria that involves essentially only light chains does not cause hyperalbuminuria. Usually, there is very little albumin in the urine because glomerular function is intact. Patients with myeloma may present with acute renal failure at the time of diagnosis, or acute renal failure may manifest itself during the course of disease. In a study done at Oxford, it was noted that among patients admitted for acute renal failure, there was an excess of LCMMs and IgD myelomas (10, 12 ).
Various laboratory markers are used for the diagnosis and monitoring of patients with multiple myeloma. Among the protein components, serum M peaks and/or BJPs are identifiable in virtually all patients with the disease (13-16 ) .
A major pitfall in the measurement of urinary light chains is that dipsticks for detecting proteinuria are unreliable in recognizing free light chains. Additionally, the conventional tests used for detecting BJPs are falsely negative in approximately one-half of patients with LCMM. Because of the high urinary concentration of light chains, 24-h urine collections have traditionally been used for the detection of light chains in patients with suspected multiple myeloma. Moreover, the amount of light chain excreted in the urine often correlates with disease progression. However, 24-h urine collections are cumbersome and are prone to inaccuracies because of incorrect collection, and measurement of urinary light chains by electrophoresis is difficult. It is therefore clinically relevant to develop a modality to measure free light chains in the serum as a viable alternative to measuring BJPs to follow the course of disease in this group of patients.
As part of another research project, a registry of 29 500 dysproteinemic patients identified at the Mayo Clinic from 1960 to the present is maintained. From this registry, 28 patients with LCMM were selected for this analysis. This study was conducted with approval from the Institutional Review Board. A previously described nephelometric assay, performed using a Dade Behring BNII nephelometer [Ref. (17 ) 
